Literature DB >> 29509434

Assessment of hepatic insulin extraction from in vivo surrogate methods of insulin clearance measurement.

Isaac Asare-Bediako1, Rebecca L Paszkiewicz1, Stella P Kim1, Orison O Woolcott1, Cathryn M Kolka1, Miguel Burch2, Morvarid Kabir1, Francesca Piccinini1, Richard N Bergman1.   

Abstract

Hyperinsulinemia, accompanied by reduced first-pass hepatic insulin extraction (FPE) and increased secretion, is a primary response to insulin resistance. Different in vivo methods are used to estimate the clearance of insulin, which is assumed to reflect FPE. We compared two methodologically different but commonly used indirect estimates with directly measured FPE in healthy dogs ( n = 9). The indirect methods were 1) metabolic clearance rate of insulin (MCR) during the hyperinsulinemic-euglycemic clamp (EGC), a steady-state method, and 2) fractional clearance rate of insulin (FCR) during the frequently sampled intravenous glucose tolerance test (FSIGT), a dynamic method. MCR was calculated as the ratio of insulin infusion rate to steady-state plasma insulin. FCR was calculated as the exponential decay rate constant of the injected insulin. Directly measured FPE is based on the difference in insulin measurements during intraportal vs. peripheral vein insulin infusions. We found a strong correlation between indirect FCR (min-1) and FPE (%). In contrast, we observed a poor association between MCR (ml·min-1·kg-1) and FPE (%). Our findings in canines suggest that FCR measured during FSIGT can be used to estimate FPE. However, MCR calculated during EGC appears to be a poor surrogate for FPE.

Entities:  

Keywords:  hepatic insulin extraction; insulin catabolism; insulin clearance; liver

Mesh:

Substances:

Year:  2018        PMID: 29509434      PMCID: PMC6230713          DOI: 10.1152/ajpendo.00344.2017

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  41 in total

1.  Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals.

Authors:  C N Jones; D Pei; P Staris; K S Polonsky; Y D Chen; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

2.  Distribution and binding of insulin in the dog hindlimb.

Authors:  P H Sonksen; J R McCormick; R H Egdahl; J S Soeldner
Journal:  Am J Physiol       Date:  1971-12

Review 3.  The kinetics of insulin in man. II. Role of the liver.

Authors:  E Ferrannini; C Cobelli
Journal:  Diabetes Metab Rev       Date:  1987-04

4.  Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin.

Authors:  P A Jansson; J P Fowelin; H P von Schenck; U P Smith; P N Lönnroth
Journal:  Diabetes       Date:  1993-10       Impact factor: 9.461

5.  Role of the kidney in the disposal of radioiodinated and nonradioiodinated insulin in dogs.

Authors:  D S Zaharko; L V Beck; R Blankenbaker
Journal:  Diabetes       Date:  1966-09       Impact factor: 9.461

Review 6.  Interaction of insulin with the renal proximal tubular cell.

Authors:  M R Hammerman
Journal:  Am J Physiol       Date:  1985-07

7.  Direct assessment of splanchnic uptake and metabolic effects of human and porcine insulin.

Authors:  L Saccà; G Orofino; A Petrone; C Vigorito
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

8.  Quantitative study of insulin secretion and clearance in normal and obese subjects.

Authors:  K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

9.  Insulin uptake across the luminal membrane of the rat proximal tubule in vivo and in vitro.

Authors:  Pavel Kolman; Angelo Pica; Nicolas Carvou; Alan Boyde; Shamshad Cockcroft; Andrew Loesch; Arnold Pizzey; Mariadelina Simeoni; Giovambattista Capasso; Robert J Unwin
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

10.  Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog.

Authors:  Marilyn Ader; Darko Stefanovski; Stella P Kim; Joyce M Richey; Viorica Ionut; Karyn J Catalano; Katrin Hucking; Martin Ellmerer; Gregg Van Citters; Isabel R Hsu; Jenny D Chiu; Orison O Woolcott; Lisa N Harrison; Dan Zheng; Maya Lottati; Cathryn M Kolka; Vahe Mooradian; Justin Dittmann; Sophia Yae; Huiwen Liu; Ana Valeria B Castro; Morvarid Kabir; Richard N Bergman
Journal:  Obesity (Silver Spring)       Date:  2013-12-03       Impact factor: 5.002

View more
  5 in total

1.  Hypothesis: Role of Reduced Hepatic Insulin Clearance in the Pathogenesis of Type 2 Diabetes.

Authors:  Richard N Bergman; Francesca Piccinini; Morvarid Kabir; Cathryn M Kolka; Marilyn Ader
Journal:  Diabetes       Date:  2019-09       Impact factor: 9.461

Review 2.  The Measurement of Insulin Clearance.

Authors:  Francesca Piccinini; Richard N Bergman
Journal:  Diabetes Care       Date:  2020-09       Impact factor: 19.112

3.  Quantitative path to deep phenotyping: Possible importance of reduced hepatic insulin degradation to type 2 diabetes mellitus pathogenesis.

Authors:  Richard N Bergman; Francesca Piccinini; Isaac Asare Bediako; Morvarid Kabir; Cathryn Kolka; David Polidori; Marilyn Ader
Journal:  J Diabetes       Date:  2018-07-02       Impact factor: 4.006

4.  Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity.

Authors:  Meera Ladwa; Oluwatoyosi Bello; Olah Hakim; Maria Linda Boselli; Fariba Shojaee-Moradie; A Margot Umpleby; Janet Peacock; Stephanie A Amiel; Riccardo C Bonadonna; Louise M Goff
Journal:  Acta Diabetol       Date:  2021-10-18       Impact factor: 4.280

5.  Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance.

Authors:  Amalia Gastaldelli; Muhammad Abdul Ghani; Ralph A DeFronzo
Journal:  Diabetes       Date:  2020-10-19       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.